First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.,Journal of Clinical Oncology

当前位置： X-MOL 学术 › J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2024-05-29 , DOI: 10.1200/jco.2024.42.16_suppl.3005
Timothy A. Yap ₁ , Nehal J. Lakhani ₂ , Amita Patnaik ₃ , Elizabeth Katherine Lee ₄ , Martin Gutierrez ₅ , Kathleen N. Moore ₆ , Benedito A. Carneiro ₇ , John L. Hays ₈ , Marilyn Huang ₉ , Patricia LoRusso ₁₀ , Andrew Wylie ₁₁ , Louise Cadzow ₁₁ , Matthew Goulet ₁₁ , Erica Tobin ₁₁ , Oliver Krieter ₁₂ , Daniela Schmid ₁₂ , Sophia M. Blake ₁₂ , Max Dieterich ₁₃ , Candice Jamois ₁₃ , Patricia M. Harris ₁₁

Affiliation

The University of Texas MD Anderson Cancer Center, Houston, TX
START Midwest, Grand Rapids, MI
START San Antonio, San Antonio, TX
Dana-Farber Cancer Institute, Boston, MA
Hackensack University Medical Center, Hackensack, NJ
OU Health Stephenson Cancer Center, Oklahoma City, OK
Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, RI
The Ohio State University, Columbus, OH
UVA Health, Charlottesville, VA
Yale Cancer Center, New Haven, CT
KSQ Therapeutics, Lexington, MA
Roche Pharma Research and Early Development, Roche Innovation Center, Munich, Germany
Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland

Journal of Clinical Oncology, Volume 42, Issue 16_suppl, Page 3005-3005, June 2024.

中文翻译：

口服首创泛素特异性肽酶 1 (USP1) 抑制剂 KSQ-4279 (KSQi) 的首次人体 I 期试验，作为单药 (SA) 并与奥拉帕尼 (OLA) 或卡铂 (CARBO) 联用）患有晚期实体瘤的患者（pts），富含有害的同源重组修复（HRR）突变。

《临床肿瘤学杂志》，第 42 卷，第 16 期_suppl，第 3005-3005 页，2024 年 6 月。

更新日期：2024-05-30

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南